Stock Update: Celgene Corporation (NASDAQ:CELG) – UBS Sees Celgene Beating EPS Estimates; Stock Rises 3.5%

December 05, 2013 at 10:46 AM EST

[at Barrons.com] – The biotech rally has been good to Celgene (CELG), which has soared more than 160% over the last two years. In a note published Thursday morning, analyst Matthew Roden and . . . → Read More: Stock Update: Celgene Corporation (NASDAQ:CELG) – UBS Sees Celgene Beating EPS Estimates; Stock Rises 3.5% Similar posts: Medtronic Inc. (NYSE:MDT) | Medtronic second-quarter earnings rise; top estimates AT&T Inc. (NYSE:T) – Vodafone rises on report of AT&T takeover interest Surface RT recovery image released to fix Windows RT 8.1 update issues – Microsoft Corporation (NYSE:MSFT)

Celgene Corporation (NASDAQ:CELG) [at Barrons.com] – The biotech rally has been good to Celgene (CELG), which has soared more than 160% over the last two years. In a note published Thursday morning, analyst Matthew Roden and his team upgraded Celgene to a Buy from a Neutral and set a $200 price target, citing their conviction that the drug maker can deliver 26% average annual EPS growth over the next four years. At $165, Celgene rose 3.5% in morning market action. Celgene makes drugs that treat blood … [visit site to read more]